CD8A and neoplasm: Immunochemotherapy was associated with on‐treatment tumour microenvironment (TME) remodelling, including upregulation of anti‐TMEs signatures, downregulation of pro‐TMEs signatures, reversing CD8+ T exhaustion, and repolarizing proinflammatory TAMs.